KALY Previews Investment Commitment Into Its Cannabis Biopharmaceutical Technology
February 03 2020 - 10:42AM
InvestorsHub Cannabis NewsWire
KALY Previews Investment Commitment
Into Its Cannabis Biopharmaceutical Technology
Dallas, TX -- February 3, 2020 --
InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today previewed a letter of intent (LOI)
executed with a third-party investor. The LOI details are
anticipated to be released tomorrow. Management indicates the
two-stage investment is of substantial magnitude and can
meaningfully advance the company’s ongoing development of its
cannabis biopharmaceutical technology. KALY has a U.S.
Patented Cannabis Extraction Process it uses to produce proprietary
formulations for the treatment of various medical conditions.
The proposed investment values KALY’s cannabis biopharmaceutical
technology at $50 million.
KALY's cannabis biopharmaceutical
technology intellectual property portfolio contains a deep pipeline
of cannabinoid product candidates including four distinct compounds
listed here:
- Chronic Obstructive Pulmonary
Disease (COPD) - The market for COPD treatment is anticipated
to reach $14 billion by 2025;
- Type 2 Diabetes - The market
for Type 2 Diabetes is expected to be a $64 billion market by
2026;
- Cancer Pain Management - The
overall pain management treatment market is anticipated to reach
$83 billion by 2024, and
- Epilepsy - The market for
epilepsy treatment is anticipated to reach $9 billion by
2022.
In conjunction with the research already
conducted and the next phase of research now moving forward, KALY
recently filed for a new patent application specifically on its
formulation for symptoms associated with COPD and other similar
respiratory conditions. KALY also filed for a trademark on
the name RespRx as the brand name for its CBD formulation to treat
the symptoms associated with COPD and other similar respiratory
conditions. The market for COPD treatment is anticipated to
reach $14 billion by 2025.
In addition to KALY's ongoing efforts to
develop prescription therapies, KALY has initiated a program to
certify its proprietary CBD extracts derived from KALY's U.S.
Patented Extraction Process as an Over-The-Counter (OTC) drug under
the requirements prescribed by the U.S. Food and Drug
Administration.
Follow further developments
at
https://www.kali-extracts.com/
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Sep 2023 to Sep 2024